Cipla Expands its Partnership with Alvotech to Commercialize Biosimilars in Australia and New Zealand
Shots:
- The companies collaborated for marketing and distribution of four biosimilars in Australia and New Zealand
- Cipla Gulf will be responsible for commercialization of patented biosimilars of the biologic medicine brands- covering therapeutic categories across immunology- osteoporosis- oncology as well as ophthalmology
- Alvotech will manufacture and develop the products and will be distributed by Cipla Gulf through Australia and New Zealand distribution networks. Earlier- in Jun 2019- Cipla collaborated with Alvotech for the commercialization of AVT02- an adalimumab biosimilar- in select emerging markets
Ref: Businesswire | Image: Cipla
Click here to read the full press release
This content piece was prepared by our former Senior Editor. She had expertise in life science research and was an avid reader. For any query reach out to us at connect@pharmashots.com